DrugPatentWatch Database Preview

Details for Patent: 10,391,094

« Back to Dashboard

Which drugs does patent 10,391,094 protect, and when does it expire?

Patent 10,391,094 protects INREBIC and is included in one NDA.

This patent has thirty-four patent family members in twenty-four countries.

Summary for Patent: 10,391,094

Title:	Compositions and methods for treating myelofibrosis
Abstract:	Provided herein are compositions and methods for treating myelofibrosis in a subject. The methods comprise administering to the subject an effective amount of compound which is which is N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyr- imidin-4-yl)amino]benzenesulfonamide or a pharmaceutical salt thereof or a hydrate thereof.
Inventor(s):	Jayan; Arvind (La Jolla, CA), Cacace; Janice (Miami, FL)
Assignee:	Impact Biomedicines, Inc. (Summit, NJ)
Application Number:	13/888,096
Patent Claim Types: see list of patent claims	Use; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 10,391,094

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Impact	INREBIC	fedratinib hydrochloride	CAPSULE;ORAL	212327-001	Aug 16, 2019		RX	Yes	Yes			Y			TREATMENT OF ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS

International Family Members for US Patent 10,391,094

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010363329
Australia	2011323108
Brazil	112013011184